07:00 , Oct 5, 2009 |  BioCentury  |  Emerging Company Profile

Quantum Immunologics: Going to School

Quantum Immunologics Inc. Tampa, Fla. Technology: Autologous dendritic cell immunotherapy containing oncofetal antigen/immature laminin receptor protein (OFA/iLRP) Disease focus: Cancer Clinical status: Phase I/II Founded: 2008 by Charles Broes University collaborators: University of South Alabama...
07:00 , Oct 5, 2009 |  BioCentury  |  Emerging Company Profile

Quantum Immunologics: Going to School

Quantum Immunologics Inc. is developing an autologous dendritic cell therapy that it says applies lessons learned from Dendreon Corp. 's path through the clinic with Provenge sipuleucel-T. Where Quantum says it is differentiated from other...
07:00 , Jul 27, 2009 |  BC Week In Review  |  Clinical News

Dendritic cell vaccine: Phase I/II restarted

Quantum restarted an open-label, U.S. Phase I/II trial to evaluate 3 doses of its intradermal dendritic cell vaccine given monthly in 27 patients. The company said the study, which originally started at a single university...
07:00 , May 19, 2008 |  BC Week In Review  |  Clinical News

Affimed preclinical data

In a tumorigenic fibrosarcoma cell line, IgG1-iS18 reduced the number of invasive cells by 38% compared with untreated cells (p=0.03). The antibody against laminin receptor precursor/laminin receptor (LRP/LR) also reduced cell adhesion by 70% vs....
07:00 , May 19, 2008 |  BioCentury  |  Product Development

Metastatic target in the basement

Although researchers discovered in 1984 that the laminin receptor precursor/laminin receptor (LRP/LR) is overexpressed in tumor tissue compared with normal tissue, until recently there has been minimal interest because a basement membrane receptor involved in...
07:00 , May 5, 2008 |  BC Week In Review  |  Clinical News

Anti-cancer immunotherapy: Phase I/II started

Quantum began an open-label, U.S. Phase I/II trial to evaluate 3 doses of the vaccine immunotherapy given every 2-3 weeks in 25 patients who have not responded to traditional therapies. The immunizing protein is an...
07:00 , Apr 30, 2007 |  BC Week In Review  |  Clinical News

PCK3145: Phase I/II data

Ambrilia Biopharma Inc. (TSX:AMB), Verdun, Quebec   Product: PCK3145   Business: Cancer   Molecular target: Laminin receptor   Description: Synthetic peptide analog of prostate secretory protein ( PSP94 )   Indication: Treat hormone-refractory prostate cancer...
07:00 , Jun 13, 2005 |  BC Week In Review  |  Clinical News

PCK3145: Phase IIa data

Data from an open-label, dose-escalation, U.K. Phase IIa trial in 16 patients showed 7 patients had stable disease and 1 patient had a partial response after 2 cycles of treatment with IV PCK3145. A reduction...